BMS 813160

Drug Profile

BMS 813160

Alternative Names: BMS813160

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Pyrazoles; Triazines
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 19 Jun 2017 Bristol-Myers Squibb plans a phase I/II trial for Colorectal cancer and Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease) in USA and Canada (NCT03184870)
  • 01 Jun 2015 Bristol-Myers Squibb completes a phase IIa trial for Diabetic nephropathies in USA, Canada, Denmark and France (NCT01752985)
  • 07 Jan 2015 Phase-II clinical trials in Diabetic nephropathies in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top